Global Point of Care
America is opening again. Even as more Americans get vaccinated, millions of unvaccinated adults and children are still carrying the virus, new COVID-19 variants threaten our return to normal and possible seasonal surges loom this fall and winter. BinaxNOW is the faster, simpler, more affordable and more accessible innovation in testing that we need to return to life with confidence.
As schools, businesses and our communities move to reopen and stay open, this critical testing technology means institutions and industry can turn the page on long wait times for test results and adopt new simple testing protocols that meet their needs now and move us all forward.
Regular, rapid COVID-19 self-testing – that is simple to do, easy to afford, quick with results – lets us all do more than reopen. We can stay open and stay together.
Abbott is intently monitoring the mutations of COVID-19 so we can ensure our tests can detect them. We have conducted a computational analysis of the new variants, including the Delta variant, and we are confident that our tests remain effective. The Delta variant, along with all other variants of concern, are primarily defined by mutations in the spike protein. Abbott's diagnostic tests do not rely on the spike proteins to detect the virus, which means that these new variants do not affect test performance.
Based on our analysis, the sensitivity and specificity of our tests, including our BinaxNOW rapid antigen tests, are not impacted by the Delta variant. Learn more about Abbott's evaluation of the Delta variant and our commitment to monitoring COVID-19 variants to ensure test effectiveness.
The BinaxNOW COVID-19 Antigen Self Test has received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA).
Abbott is intently monitoring the mutations of COVID-19 so we can ensure our tests can detect them. We have conducted a computational analysis of the new variants, including the Delta variant, and we are confident that our tests remain effective. The Delta variant, along with all other variants of concern, are primarily defined by mutations in the spike protein. Abbott's diagnostic tests do not rely on the spike proteins to detect the virus, which means that these new variants do not affect test performance.
Based on our analysis, the sensitivity and specificity of our tests, including our BinaxNOW rapid antigen tests, are not impacted by the Delta variant. Learn more about Abbott's evaluation of the Delta variant and our commitment to monitoring COVID-19 variants to ensure test effectiveness.
The BinaxNOW COVID-19 Antigen Self Test has received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA).
I am interested in tests for our K-12 schools or colleges and universities.
I am interested in COVID-19 testing for myself or learning more about the test.
Schools are opening again. As we balance smart precautions that help keep students and educators healthy, with the drive to bring classrooms back to life, BinaxNOW Self Test will enable our schools to move forward with confidence. Now, students and educators can learn if they are infectious within 15 minutes, before even going to school, rather than testing and quarantining whole classrooms for days waiting for test results.
By providing testing at greater scale and with greater frequency, rapid COVID-19 self-testing will mean schools don’t just reopen. They can stay open and stay in-person.
Northwestern University, an iconic research university just outside of Chicago, launched a successful university-wide COVID-19 rapid self-testing program for students, faculty, staff and contract employees allowing them to test as frequently as they wanted and know their COVID-19 status before leaving their home. Using BinaxNOW for regular testing has allowed their campus to stay open and in-person.
In a July 2021 survey, 68% of parents see regular testing as a critical component to keep schools open for in-person learning.
Mitigation and Testing Strategies for K-12 School Districts
Speaker Mara G. Aspinall, Professor of Practice, Arizona State University
|
Plug & Play
|
TechnologyUtilizes school’s existing tracking platform. Examples of platforms we can support: PowerSchool and Phoenix. |
Pre-test user communicationsList of pre-defined screening questions and symptom checker for reference. |
Self test guidanceDigital tool kit including: - Step-by-step procedure guide (PDF and videos) |
REPORTING
|
Abbott serviceTesting support as needed. |
|
|
|
Full-service solution
|
TechnologyUtilizes Abbott's NAVICA system – including app and web portal interfaces for individual testing. |
Pre-test user communicationsAutomated text and/or email reminders to complete testing. |
Self test guidanceDigital tool kit including: - Step-by-step procedure guide (PDF and videos) Step by step interactive guidance for conducting tests through NAVICA system. |
REPORTING
|
Abbott serviceFull-service support across end-to-end process to mobilize and operate. |
|
|
|
Plug & Play
|
Full-service solution
|
|
Technology |
Utilizes school’s existing tracking platform. Examples of platforms we can support: PowerSchool and Phoenix. |
Utilizes Abbott's NAVICA system – including app and web portal interfaces for individual testing. |
Pre-test user communications |
List of pre-defined screening questions and symptom checker for reference. |
Automated text and/or email reminders to complete testing. |
Self test guidance |
Digital tool kit including: - Step-by-step procedure guide (PDF and videos) |
Digital tool kit including: - Step-by-step procedure guide (PDF and videos) Step by step interactive guidance for conducting tests through NAVICA system. |
Reporting |
Handled by school through existing platform. |
Ability to support CARES/Federal/State reporting. |
Abbott service |
Testing support as needed. |
Full-service support across end-to-end process to mobilize and operate. |
|
|
|
Businesses are opening again. BinaxNOW COVID-19 Antigen Self Test meets the needs of those businesses today and will give employees the confidence to return to in-person work and move forward. Each workplace is different – whether it’s a factory, a small retail storefront, or a large collaborative corporate office – and rapid self-testing with BinaxNOW allows businesses of all types and sizes to customize testing protocol to serve their unique workforce.
Rapid COVID-19 self-testing will mean businesses in every community can do more than open, they can stay open and stay thriving.
Abbott created a BinaxNOW rapid testing protocol and deployed across 40 worksites – from the factory floor to corporate headquarters. That protocol allowed Abbott to stay open since Fall 2020, with less than 1% positivity across all locations.
Read more about Abbott Laboratories’ successful BinaxNOW Pilot Program utilizing the BinaxNOW™ COVID-19 Ag Card.
This video will show you how to use the BinaxNOW COVID-19 Antigen Self Test.
The BinaxNOW™ COVID-19 Antigen Self Test has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization. It has been authorized only for the detection of proteins from SARSCoV-2, not for any other viruses or pathogens, and are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. BinaxNOW COVID-19 Antigen Self Test should be performed twice in 3 days, at least 36 hours apart.
a leader in rapid point-of-care diagnostics.
©2023 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.
Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement | Declaration for California Compliance Law.
Not all products are available in all regions. Check with your local representative for availability in specific markets. For in vitro diagnostic use only. For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.
Abbott - A Leader in Rapid Point-of-Care Diagnostics.
